Ignite Creation Date:
2025-12-24 @ 6:49 PM
Ignite Modification Date:
2026-02-28 @ 11:18 AM
Study NCT ID:
NCT05088057
Status:
UNKNOWN
Last Update Posted:
2021-10-21
First Post:
2021-10-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Sponsor:
Aiping Shi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08-19
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-10-11
First Submit QC Date:
None
Study First Post Date:
2021-10-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-11
Last Update Post Date:
2021-10-21
Last Update Post Date Type:
ACTUAL